Bahrain's National Health Regulatory Authority (NHRA) has approved the emergency use of the Evusheld to combat Covid-19, making the Kingdom the first country to utilise the drug.

 

The drug will be available to adults 18 years and above, who are immunocompromised or who are taking immunosuppressive drugs, or for individuals with occupations that put them at risk of infection, said a Bahrain News Agency report.

 

The decision follows the evaluation of data provided by the manufacturer AstraZeneca, carried out by the NHRA's Pharmaceutical Products Regulation department, it said. 

 

Evusheld is made from a mixture of two antibodies, which achieved a “statistically significant decrease in cases of acute or fatal Covid-19 infection” in patients who were not hospitalised and those with symptoms ranging from mild to moderate, it said.